Better Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	0	0.01	0.02
Revenue Growth (YoY)	-	-	-	-55.56%	-
Cost of Revenue	3.11	2.73	1.62	0.68	0.9
Gross Profit	-3.11	-2.73	-1.62	-0.67	-0.88
Selling, General & Admin	19.1	21.82	11.12	2.67	2.6
Research & Development	10.51	16.44	19.44	2.98	2.29
Operating Expenses	29.61	38.26	30.56	5.65	4.89
Operating Income	-29.61	-38.26	-30.56	-6.32	-5.77
Interest Income	0	0	0	0	0
Interest Expense	0.92	1.49	0.19	0.1	0.01
Other Expense / Income	1.04	0	9.74	-0.19	0
Pretax Income	-31.56	-39.75	-40.49	-6.23	-5.78
Income Tax	0.01	0.01	-0.15	0.15	0.01
Net Income	-31.57	-39.76	-40.34	-6.39	-5.8
Shares Outstanding (Basic)	38	24	24	8	24
Shares Outstanding (Diluted)	38	24	24	8	24
Shares Change	62.47%	-0.19%	212.31%	-67.98%	-
EPS (Basic)	-1.15	-1.69	-1.71	-0.85	-0.25
EPS (Diluted)	-1.15	-1.69	-1.71	-0.85	-0.25
Free Cash Flow	-27.47	-30.11	-31.89	-8.08	-8.95
Free Cash Flow Per Share	-0.71	-1.28	-1.35	-1.07	-0.38
Gross Margin	-	-	-	-8425.00%	-4888.89%
Operating Margin	-	-	-	-79037.50%	-32072.22%
Profit Margin	-	-	-	-79837.50%	-32194.44%
Free Cash Flow Margin	-	-	-	-100987.50%	-49738.89%
EBITDA	-28.82	-38.26	-30.56	-6.25	-5.7
EBITDA Margin	-	-	-	-78100.00%	-31672.22%
Depreciation & Amortization	3.11	2.73	1.62	0.08	0.07
EBIT	-31.93	-40.99	-32.18	-6.32	-5.77
EBIT Margin	-	-	-	-79037.50%	-32072.22%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.